Recently, Shanghai Municipal Science and Technology Commission announced the "List of Projects of Shanghai 2023 Technology Innovation Funding Program for Small and Medium-sized Enterprises (SMEs)". After the strict evaluation and selection by the expert group of Shanghai Municipal Science and Technology Commission, "Preclinical Research of PROTAC Innovative Drugs" declared by Leadingtac was awarded the project.

About Technology Innovation Fund for Science and Technology-based Small and Medium-sized Enterprises：

Technology Innovation Fund for Science and Technology-based Small and Medium-sized Enterprises (SMEs) is a special fund support program established by Shanghai Municipal Science and Technology Commission for science and technology-based SMEs in accordance with the "Shanghai Technology Innovation Fund for Science and Technology-based Small and Medium-sized Enterprises Program Management Measures". The purpose of this innovation fund is to promote the implementation of the innovation-driven development strategy, improve the efficiency of scientific and technological innovation, encourage "mass entrepreneurship and innovation", support services for scientific and technological small and medium-sized enterprises to carry out innovation and entrepreneurship, and increase the promotion of the three major pilot industries of integrated circuits, biopharmaceuticals and artificial intelligence, as well as the development of the scientific research and technological service industry.

About Leadingtac：

Founded in 2019, Leadingtac is a clinical-stage biopharmaceutical company dediated to the discovery and development of First-in-class/Best-in-class small molecule innovative therapies using Protein Degradation (TPD) drug development platform with a focus on autoimmune and oncology, two therapeutic areas with great clinical unmet needs: autoimmune disease and oncology, providing breakthrough therapeutic solutions for patients. Located in Zhangjiang Science City, Shanghai, China, Leadingtac has nearly 1000 square meters of laboratory and office space, nearly 20 employees, and has raised nearly CNY￥100 million in funding since its inception 4 years ago.